These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 16682724)

  • 41.
    Nienhuis HH; van Kruchten M; Elias SG; Glaudemans AWJM; de Vries EFJ; Bongaerts AHH; Schröder CP; de Vries EGE; Hospers GAP
    J Nucl Med; 2018 Aug; 59(8):1212-1218. PubMed ID: 29602822
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.
    Groheux D; Hatt M; Hindié E; Giacchetti S; de Cremoux P; Lehmann-Che J; Martineau A; Marty M; Cuvier C; Cheze-Le Rest C; de Roquancourt A; Visvikis D; Espié M
    Cancer; 2013 Jun; 119(11):1960-8. PubMed ID: 23504954
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical Validity of 16α-[
    van Geel JJL; Boers J; Elias SG; Glaudemans AWJM; de Vries EFJ; Hospers GAP; van Kruchten M; Kuip EJM; Jager A; Menke-van der Houven van Oordt WC; van der Vegt B; de Vries EGE; Schröder CP;
    J Clin Oncol; 2022 Nov; 40(31):3642-3652. PubMed ID: 35584346
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays.
    Dehdashti F; Mortimer JE; Siegel BA; Griffeth LK; Bonasera TJ; Fusselman MJ; Detert DD; Cutler PD; Katzenellenbogen JA; Welch MJ
    J Nucl Med; 1995 Oct; 36(10):1766-74. PubMed ID: 7562040
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma.
    van Kruchten M; Glaudemans AW; de Vries EF; Beets-Tan RG; Schröder CP; Dierckx RA; de Vries EG; Hospers GA
    J Nucl Med; 2012 Feb; 53(2):182-90. PubMed ID: 22241912
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fully automated radiosynthesis and quality control of estrogen receptor targeting radiopharmaceutical 16α-[
    Wang M; Glick-Wilson BE; Zheng QH
    Appl Radiat Isot; 2020 Jun; 160():109109. PubMed ID: 32174461
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications.
    Kurland BF; Wiggins JR; Coche A; Fontan C; Bouvet Y; Webner P; Divgi C; Linden HM
    Oncologist; 2020 Oct; 25(10):835-844. PubMed ID: 32374053
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Temporal Heterogeneity of Estrogen Receptor Expression in Bone-Dominant Breast Cancer: 18F-Fluoroestradiol PET Imaging Shows Return of ER Expression.
    Currin E; Peterson LM; Schubert EK; Link JM; Krohn KA; Livingston RB; Mankoff DA; Linden HM
    J Natl Compr Canc Netw; 2016 Feb; 14(2):144-7. PubMed ID: 26850484
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PET imaging of breast cancer with fluorine-18 radiolabeled estrogens and progestins.
    Jonson SD; Welch MJ
    Q J Nucl Med; 1998 Mar; 42(1):8-17. PubMed ID: 9646640
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Breast cancer models to study the expression of estrogen receptors with small animal PET imaging.
    Aliaga A; Rousseau JA; Ouellette R; Cadorette J; van Lier JE; Lecomte R; Bénard F
    Nucl Med Biol; 2004 Aug; 31(6):761-70. PubMed ID: 15246367
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of the novel estrogen receptor PET tracer 4-fluoro-11β-methoxy-16α-[(18)F]fluoroestradiol (4FMFES) by PET imaging in a breast cancer murine model.
    Paquette M; Phoenix S; Ouellet R; Langlois R; van Lier JE; Turcotte EE; Bénard F; Lecomte R
    Mol Imaging Biol; 2013 Oct; 15(5):625-32. PubMed ID: 23619898
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 18F-Fluoroestradiol PET: Current Status and Potential Future Clinical Applications.
    Liao GJ; Clark AS; Schubert EK; Mankoff DA
    J Nucl Med; 2016 Aug; 57(8):1269-75. PubMed ID: 27307345
    [TBL] [Abstract][Full Text] [Related]  

  • 53.
    Kumar M; Salem K; Michel C; Jeffery JJ; Yan Y; Fowler AM
    J Nucl Med; 2019 Sep; 60(9):1247-1252. PubMed ID: 30850489
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Summary: SNMMI Procedure Standard/EANM Practice Guideline for Estrogen Receptor Imaging of Patients with Breast Cancer Using 16α-[
    Mankoff D; Balogová S; Dunnwald L; Dehdashti F; DeVries E; Evangelista L; Van Kruchten M; Vaz SC; Fowler A; Linden H; Ulaner GA
    J Nucl Med; 2024 Feb; 65(2):221-223. PubMed ID: 38071554
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16α-18F-fluoro-17β-estradiol PET/CT.
    van Kruchten M; de Vries EF; Arts HJ; Jager NM; Bongaerts AH; Glaudemans AW; Hollema H; de Vries EG; Hospers GA; Reyners AK
    J Nucl Med; 2015 Jan; 56(1):50-5. PubMed ID: 25476534
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical and economic outcomes of adding [18F]FES PET/CT in estrogen receptor status identification in metastatic and recurrent breast cancer in the US.
    Munter-Young R; Fuentes-Alburo A; DiGregorio N; Neeser K; Gultyaev D
    PLoS One; 2024; 19(5):e0302486. PubMed ID: 38743917
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic significance of preoperative
    Higuchi T; Nishimukai A; Ozawa H; Fujimoto Y; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Kitajima K; Fukushima K; Miyoshi Y
    Breast; 2016 Dec; 30():5-12. PubMed ID: 27569020
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interactions of 16alpha-[18F]-fluoroestradiol (FES) with sex steroid binding protein (SBP).
    Tewson TJ; Mankoff DA; Peterson LM; Woo I; Petra P
    Nucl Med Biol; 1999 Nov; 26(8):905-13. PubMed ID: 10708304
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 18F-Fluoroestradiol Tumor Uptake Is Influenced by Structural Components in Breast Cancer.
    Takahashi M; Maeda H; Tsujikawa T; Kono H; Mori T; Kiyono Y; Okazawa H; Noriki S; Imamura Y; Goi T
    Clin Nucl Med; 2021 Nov; 46(11):884-889. PubMed ID: 34319950
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.
    Groheux D; Majdoub M; Sanna A; de Cremoux P; Hindié E; Giacchetti S; Martineau A; de Roquancourt A; Merlet P; Visvikis D; Resche-Rigon M; Hatt M; Espié M
    Radiology; 2015 Nov; 277(2):358-71. PubMed ID: 25915099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.